What does Ozempic have to do with a venomous desert lizard that spends most of its life underground?
This story starts at 3am with a unicorn saying the word chocolate fifteen times, and ends with the Gila monster, GLP-1, Ozempic, Wegovy and one tiny molecular difference that helped change modern medicine.
Our bodies already make GLP-1. It works beautifully, then disappears in minutes. The Gila monster carries a remarkably similar molecule called exendin-4, except nature built this one differently enough that the body’s molecular scissors struggle to cut it.
That difference helped lead to Byetta, the first GLP-1 receptor agonist, and later helped inspire a deeper biomimicry move: don’t copy the molecule. Copy the principle.
And the best part? Nobody found it by asking nature how to control appetite. An endocrinologist in the Bronx found it while looking through venom.
So this episode is about food noise, microscopic scissors, accidental discovery, a drug market worth tens of billions of dollars, and a squat pink-and-black lizard that had been sitting on the answer for millions of years.
Biology: Exendin-4, found in Gila monster saliva, can activate the same GLP-1 receptor as our own hormone but resists the rapid DPP-4 breakdown that makes native GLP-1 so short-lived.
Biomimicry: Byetta copied the Gila monster molecule directly. Later GLP-1 drugs including Ozempic and Wegovy took the underlying design principle and applied it back to human GLP-1.
Next week I’m bringing back the perfect companion from Season 1. Today, the drug. Next week, the needle.
Nature owns the patent. We copied it.
Topics: Ozempic, Wegovy, GLP-1, Gila monster, exendin-4, Byetta, biomimicry.
Sources
Exendin-4 and the Gila monster
Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Journal of Biological Chemistry. 1992;267(11):7402–7405.
GLP-1 physiology and DPP-4 - the biomimicry claim
Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia. 1998;41(3):271–278. doi:10.1007/s001250050903.
Semaglutide design
Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler JC, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370–7380. doi:10.1021/acs.jmedchem.5b00726.
Drucker DJ, Habener JF, Holst JJ, et al. The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity. Proceedings of the National Academy of Sciences. 2024;121(39):e2415550121. doi:10.1073/pnas.2415550121.
Knudsen LB, "Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity." ACS Pharmacol Transl Sci 2019;2(6):468–484. doi:10.1021/acsptsci.9b00048
Patient experience
de Vere Hunt I, Ramirez-Posada M, Babu CS, Brown-Johnson C, Linos E, Rodriguez F. Patient Experiences With GLP-1 Receptor Agonists. JAMA Network Open. 2026;9(6):e2616951. doi:10.1001/jamanetworkopen.2026.16951.
Global music industry stats - $31.7billion in 2025
https://www.ifpi.org/global-music-report-2026-global-recorded-music-revenues-grow-6-4-as-record-companies-drive-innovation/
Moonbow Unicorn Forest Bedtime story
https://insighttimer.com/corycochiolo/guided-meditations/moonbow-unicorn-forest-childrens-bedtime-story-slash-meditation
S3E05
Send Pia a note
Follow Feral for new episodes every fortnight.
Instagram / Facebook / YouTube : @feralbydesignpod
feralbydesign.com
Created and hosted by Pia Williams
Clever by Nature. Feral by Design.